NCT04282044 2024-02-08
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
Phase 1 Recruiting
BioEclipse Therapeutics
ImmunoVaccine Technologies, Inc. (IMV Inc.)
ImmunoVaccine Technologies, Inc. (IMV Inc.)